Hawley Unveils Bill to Ban Abortion Pill, Strip FDA Approval

Why It Matters

If passed, the bill could eliminate a widely used, FDA‑approved medication, reshaping abortion access and exposing drug makers to new liability. It also underscores the growing clash between political agendas and evidence‑based health policy.

Key Takeaways

• Hawley proposes revoking FDA approval for mifepristone.
• Bill would allow lawsuits against drug manufacturers.
• Experts cite 99.6% efficacy and less than 1% complications.
• Conservative study claims 11% adverse events, lacks peer review.
• Abortion pills comprised over 60% of 2023 procedures.

Pulse Analysis

Senator Josh Hawley introduced legislation that would immediately rescind the Food and Drug Administration’s approval of mifepristone, the primary medication used for non‑surgical abortions. The proposal follows a series of high‑profile challenges, including a 2024 Supreme Court case that dismissed a lawsuit seeking to remove the drug from pharmacy shelves. Hawley argues that Congress, not the FDA, should decide the drug’s fate, citing a 2025 report from the Ethics and Public Policy Center that alleges serious adverse events. If enacted, the bill would also create a federal cause‑of‑action for women harmed by the medication.

Medical experts overwhelmingly contest Hawley’s safety narrative. Peer‑reviewed studies confirm that mifepristone terminates 99.6 % of pregnancies when used up to nine weeks and generates serious complications in fewer than one in a hundred cases. The controversial Ethics and Public Policy Center analysis, which reports an 11 % adverse‑event rate, has been criticized for non‑transparent data and an overly broad definition of “serious.” Moreover, the FDA’s 2020 regulatory relaxations, including telehealth prescribing during the COVID‑19 pandemic, have expanded access without measurable spikes in hospitalizations, reinforcing the drug’s established risk profile.

The bill’s passage would reverberate across the pharmaceutical and legal arenas. Stripping FDA approval could force manufacturers to withdraw the product, jeopardizing revenue streams estimated in the billions and prompting litigation over liability. At the same time, restricting a medication that also treats postpartum hemorrhage narrows clinicians’ therapeutic toolkit. State‑level bans already in place have sparked supply shortages and cross‑border travel for care, suggesting a federal ban would amplify those pressures. Ultimately, the debate spotlights a broader clash between political ideology and evidence‑based medicine, with women’s health outcomes hanging in the balance.